Patents by Inventor Christian Gege

Christian Gege has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LXR modulators with bicyclic core moiety
    Patent number: 12291523
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRa and/or LXKJ3) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: March 5, 2024
    Date of Patent: May 6, 2025
    Assignee: ORSOBIO, INC.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF
    Publication number: 20250115565
    Abstract: The present invention provides solid crystalline forms of compounds useful as helicase-primase inhibitors, compositions thereof, methods of producing the same, and methods of using the same in the treatment of herpes simplex infection and -mediated diseases.
    Type: Application
    Filed: January 16, 2023
    Publication date: April 10, 2025
    Applicant: INNOVATIVE MOLECULES GMBH
    Inventors: Gerald KLEYMANN, Christian GEGE
  • DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE
    Publication number: 20250066290
    Abstract: The invention relates to novel, optionally deuterated compounds of Formula (I) and their use as medicament.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 27, 2025
    Inventors: Christian GEGE, Andreas MÜHLER, Hella KOHLHOF, Daniel VITT
  • MEDICAL USE OF N4-HYDROXY CITICOLINE COMPOUNDS
    Publication number: 20250032527
    Abstract: The present disclosure relates to the medical use of citicoline analogs with a N4-hydroxycytidine moiety and a solvate or pharmaceutically acceptable salt thereof. The compounds can be used as antiviral drug for treatment of e.g. Covid-19, human rhinovirus (HRV), influenza and respiratory syncytial virus (RSV).
    Type: Application
    Filed: November 1, 2022
    Publication date: January 30, 2025
    Inventors: Christian GEGE, Hella KOHLHOF, Andreas MÜHLER, Daniel VITT
  • Helicase Primase Inhibitors For Treating Cancer In A Combination Therapy With Oncolytic Viruses
    Publication number: 20240408068
    Abstract: The present invention relates to the novel use of antiviral compounds, which act as helicase primase inhibitors in a combination therapy with oncolytic viruses for treating tumors, cancer or neoplasia. The antiviral compounds of the present invention lack, or show significantly reduced, carbonic anhydrase activity, showing an improved solubility and a suitable pharmacokinetic profile for cancer treatment.
    Type: Application
    Filed: July 17, 2024
    Publication date: December 12, 2024
    Inventors: Gerald Kleymann, Christian Gege
  • METHODS FOR TREATING CANCER
    Publication number: 20240368145
    Abstract: The present invention provides methods comprising one or compounds according to Formula (I) alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g. prostate cancer, such as castration-resistant prostate cancer (CRPC) and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma and glioma.
    Type: Application
    Filed: July 8, 2022
    Publication date: November 7, 2024
    Inventors: Hella KOHLHOF, Evelyn PEELEN, Christian GEGE, Daniel VITT, Andreas MÜHLER
  • VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS
    Publication number: 20240335405
    Abstract: The present invention relates to methods of treating or ameliorating a neurodegenerative disease, such as Parkinson's disease or multiple sclerosis, with a compound according to Formula (I) to (V), or with a compound according to Formula (VI), or a pharmaceutically acceptable salt or solvate thereof, for example, vidofludimus, which acts as a Nurr1 agonist.
    Type: Application
    Filed: March 29, 2024
    Publication date: October 10, 2024
    Inventors: Christian GEGE, Hella KOHLHOF, Evelyn PEELEN, Andreas MÜHLER, Daniel VITT
  • NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS
    Publication number: 20240316021
    Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Application
    Filed: June 6, 2024
    Publication date: September 26, 2024
    Inventors: Gerald KLEYMANN, Christian GEGE
  • NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY
    Publication number: 20240317726
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRa and/or LXKJ3) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: March 5, 2024
    Publication date: September 26, 2024
    Inventors: Christian GEGE, Olaf KINZEL, Eva HAMBRUCH, Manfred BIRKEL, Claus KREMOSER, Ulrich DEUSCHLE
  • DEUTERATED DHODH INHIBITORS
    Publication number: 20240199535
    Abstract: The invention relates to novel deuterated compounds of Formula (I) and their use as medicaments.
    Type: Application
    Filed: April 8, 2022
    Publication date: June 20, 2024
    Applicant: IMMUNIC AG
    Inventors: Christian GEGE, Hella KOHLHOF, Andreas MÜHLER, Daniel VITT
  • LXR modulators with bicyclic core moiety
    Patent number: 11970484
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: April 30, 2024
    Assignee: OrsoBio, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • DEUTERATED AMINOTHIAZOLE COMPOUNDS AS ANTIVIRAL COMPOUNDS
    Publication number: 20230391738
    Abstract: The invention relates to novel deuterated compounds of Formula (I) to a process for their preparation and to their use as medicament, in particular as antiviral medicament.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 7, 2023
    Inventors: Christian Gege, Gerald Kleymann
  • NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY
    Publication number: 20230357214
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: February 9, 2023
    Publication date: November 9, 2023
    Inventors: Christian GEGE, Olaf KINZEL, Eva HAMBRUCH, Manfred BIRKEL, Claus KREMOSER, Ulrich DEUSCHLE
  • FXR (NR1H4) modulating compounds
    Patent number: 11739065
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: August 29, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • LXR modulators with bicyclic core moiety
    Patent number: 11618747
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: April 4, 2023
    Assignee: OrsoBio, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20220242858
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: January 11, 2022
    Publication date: August 4, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20220204460
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: November 29, 2021
    Publication date: June 30, 2022
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Enantiomers Of Substituted Thiazoles As Antiviral Compounds
    Publication number: 20220152008
    Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 19, 2022
    Inventors: Gerald Kleymann, Christian Gege
  • Enantiomers of substituted thiazoles as antiviral compounds
    Patent number: 11278534
    Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 22, 2022
    Assignee: Innovative Molecules GmbG
    Inventors: Gerald Kleymann, Christian Gege
  • FXR (NR1H4) modulating compounds
    Patent number: 11247986
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 15, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu